• 대한핵의학회지
• /
• 제9권2호
• /
• pp.39-46
• /
• 1975

It is the purpose of this paper to design the most preferable method of erythropoietin bioassay in Korea. Bioassay utilizing polycythemic mice are currently in general use for the indirect determination of erythropoietin. Assay animals are usually prepared either by transfusion or by exposure to reduced oxygen tension in specially constructed chamber. We prepared the polycythemic, mice by the specially constructed hypobaric chamber. We observed weights and hematocrits of the mice in the hypobaric chamber, then hematocrits and 72 hours $^{59}Fe$ red cell upatke ratio of the polycythemic mice induced by hypoxia after removal from the hypobaric chamber. We designed the method of erythropoietin bioassay according to the results obtained by above experiments. Then we measured the 72 hours $^{59}Fe$ red cell uptake ratio of the polycythemic mice with normal saline, normal plasma and anemic plasma according to the method we designed. The results are followed: 1. The hematocrits of the mice in hypobaric chamber increased to 74% in 14 days It is preferable to maintain the pressure of the chamber to 400mmHg for first 4 days then 300mmHg for last 10 days to reduce the death rate and time consuming in hypobaric chamber. 2. After removal from the hypobaric chamber, the 72 hours $^{59}Fe$ red cell uptake ratio decreased rapidly and maintained the lowest level from the fourth day to tenth day. 3. We design the method of erythropoietin bioassay according to the results of above experiment and to the half life of erythropoietin. 4. The Korean product S9Fe is mixture of $^{59}Fe\;and\;^{55}Fe$. And the $^{59}Fe$ red cell uptake ratio in normal mice was far less with Korean product $^{59}Fe$ than with pure $^{59}Fe$ of foreign product. So it is desirable to use pure $^{59}Fe$ in this method of erythropoietin bioassay. 5. Considering the cost, the technique, the time consuming and the sensitivity it is the most preferable method of erythropoietin bioassay in Korea using hypobaric chamber to induce the polycythemia.

• Clinical and Experimental Pediatrics
• /
• 제49권5호
• /
• pp.489-493
• /
• 2006

목 적 : 본 연구의 목적은 만삭아에서 신생아 괴사성 장염의 위험인자를 알고자 함이다. 방 법 : 1998년 1월 1일부터 2005년 8월 1일까지 본원 소아과 신생아실에 입원한 환아 중 신생아 괴사성 장염으로 진단된 20례와 각각의 경우에 대해 짝짓기 방식으로 선정된 건강한 만삭아 40례를 대상으로 병력지 검토를 통하여 후향적으로 조사되어 졌다. 결 과 : 괴사성 장염군의 평균 재태연령과 출생 체중은 38.42주와 2,915 g이었고 대조군은 38.61주와 3,148 g이었다. 대조군과 비교 하였을 때 신생아 괴사성 장염군 환아들에서 모체의 융모 양막염, 지연된 설사, 1분 아프가 점수 <7, 호흡기 문제, 선천성 심질환의 빈도가 유의하게 높았다(유의수준 <0.05). 반면 전자간증, 모체의 당뇨, 모체의 약물 남용, 태변 착색된 양수, 다혈구증, 교환 수혈의 빈도에는 유의한 차이가 없었다. 결 론 : 만삭아들의 대부분은 괴사성 장염이 발생하기 전에 선행하는 인자가 있다. 본 연구에서는 여러 가지 유발인자들 중에 지연된 설사가 가장 큰 관련성이 있는 것으로 나타났다.

• Asian Pacific Journal of Cancer Prevention
• /
• 제16권2호
• /
• pp.443-449
• /
• 2015

Background: Myeloproliferative disorders (MPDs) are clonal hematologic malignancies originating at the level of the pluripotent hematopoietic stem cell. Matrix metalloproteases (MMPs) are proteolytic enzymes that contribute to all stages of malignancy progression. Genetic variants in the MMP genes may influence the biological function of these enzymes and change their role in carcinogenesis and progression. To our knowledge, this is the first investigation of associations between the -735 C/T and -1562 C/T polymorphisms in the MMP2 and MMP9 genes, respectively, and the risk of essential thrombocytosis (ET), and polycythemia vera (PV). Materials and Methods: The case-control study included JAK2V617F mutation positive 102 ET and PV patients and 111 controls. Polymorphisms were determined by using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) and electrophoresis. Results: No statistically significant differences were detected between patient (ET+PV) and control groups regarding genotype distribution for MMP2 gene-735 C/T and MMP9 gene -1562 C/T polymorphisms and C/T allele frequency (p>0.050). Statistically borderline significance was observed between PV and control groups regarding genotype distribution for the MMP9 gene -1562 C/T polymorphism (p=0.050, OR=2.26, 95%Cl=0.99-5.16). Conclusions: Consequently this study supported that CC genotype of MMP9 gene -1562 C/T polymorphism may be related with PV even if with borderline significance.

• 한국임상수의학회지
• /
• 제21권1호
• /
• pp.72-75
• /
• 2004

A ten months old, female Yorkshire terrier weighing 2.88 kg referred to veterinary leaching hospital of college of veterinary medicine, Konkuk University because of syncope, cough and dyspnea. First hematological and serum chemical test revealed thrombocytopenia, mild anemia, and increase of concentration of ALP (195 U/L). On 57 days later, second hematological and serum chemical test revealed polycythemia, increase of concentration of ALP (211 UR.), and Tchol (387 mg/dl). Right atrium enlargement, main pulmonary artery bulge and cardiomegaly (VHS = 11.5) were observed in radiographic findings. Ultrasohographic images showed both right and left ventricular dilation and turbulent flow between the descending aorta and the main pulmonary artery in color Doppler imaging. ECG showed left ventricular enlargement, SA block, and electrical alternant. Thoracotomy was performed through left fourth intercostal incision under isoflurane anesthesia. Patent ductus arteriosus was double ligated with 1-0 silk. Cough and dyspnea disappeared on 5 days after operation. Turbulent flow was not found in color doppler imaging of ultrasonography on 10 days after operation. Ten months later after the operation, syncope could not exist any more.

• 한국임상수의학회지
• /
• 제28권2호
• /
• pp.258-261
• /
• 2011

8연령의 암컷 요크셔 테리어견이 요실금을 주증으로 내원하였다. 환축은 요실금 증상이 나타나기 이전부터 다음다뇨 증상을 가지고 있었으며, 난소제거 8개월 이후 야뇨증이 나타났다. 신체검사 상에서 비만과 고혈압이 확인되었다. 실험실 검사에서 적혈구증가증, 지질혈증 및 간수치 증가가 관찰되었다. 다양한 검사를 통하여 난소제거 이후 발생한 요도 괄약근 기능부전증이 가장 의심되었다. 이와 더불어 본 환축은 부신피질기능 항진증을 가진 것으로 진단되었다. 합성 에스트로겐인 디에틸스틸베스테롤을 통한 치료적 접근에서 요실금 증상의 개선이 확인 되었으며, 이를 통하여 요도 괄약근 기능부전증이 요실금의 원인으로 확진 되었다. 결론적으로 본 증례는 부신피질기능 항진증과 더불어 암캐의 난소 제거 이후 발생한 요도 괄약근 기능부전의 임상증상과 실험실 검사 결과 그리고, 치료 반응에 대한 국내 첫 증례보고이다.

• 대한임상검사과학회지
• /
• 제53권1호
• /
• pp.41-48
• /
• 2021

Essential thrombocythemia (ET) is a clonal bone marrow stem cell disorder, primarily involving the megakaryocytic lineage. The WHO 2016 guidelines include the molecular detection of JAK2, MPL, and CALR mutations as a major diagnostic criterion for ET. This study aimed to determine the frequency of JAK2 V617F, MPL W515L, and CALR mutations in Iraqi Kurdish patients afflicted with ET, and to analyze their clinical and hematological features. A total of 73 Iraqi Kurdish patients with ET were enrolled as subjects, and analysis was achieved utilizing real-time PCR. The frequency of JAK2 V617F, CALR, and MPL W515L mutations was determined to be 50.7%, 22%, and 16.4%, respectively. No statistically significant difference was obtained when considering the age and gender among different genotypes. The JAK2 V617F mutated patients had significantly higher white blood cell counts and hemoglobin levels than the CALR-positive patients (P-value=0.000, 0.007, respectively), MPL W515L-positive patients (P-value=0.000, 0.000, respectively), and triple negative patients (P-value=0.000, 0.000, respectively). Also, the JAK2 V617F mutated patients showed higher platelet count as compared to the MPL W515L-positive patients (P-value=0.02) and triple negative patients (P-value=0.04). Furthermore, significantly lower white blood cell count and hemoglobin levels were associated with CALR positivity (P-value=0.000, 0.01, respectively), MPL W515L-positivity (P-value=0.001, 0.000, respectively), and triple negativity (P-value=0.000, 0.000, respectively), as compared to patients with combined mutations. In conclusion, apart from a relatively high frequency of MPL W515L mutation, our data is comparable to earlier reports, and highlights the importance of genotyping the JAK2 V617F, MPL W515L, and CALR mutations for accurate diagnosis of patients with ET.